BCI psyops has begun

[EndtheMadnessNow]

New arms race just dropped...




OmegaLogos link from shoutbox...

Synchron says it's the first to implant a human brain-computer interface in the US
...triggered some neurons.


FDA clears Synchron's brain-computer interface device for human trials



BusinessWire

History

Company co-founder and CEO Thomas Oxley a neurointerventionist at Mount Sinai Hospital in New York City, conceived the idea for the Stentrode in 2007. In 2010, Oxley made a cold-call pitch to Colonel Geoffrey Ling at the United States Army with a new concept for a brain-computer interface.

Oxley founded the Australian startup SmartStent in 2012, which was later renamed to Synchron in 2016. In 2016, Oxley co-published a proof-of-concept paper in Nature Biotechnology, demonstrating the potential for a neural recording device to be engineered onto a stent and chronically implanted into a blood vessel in the brain without the need for open brain surgery.

Funding - DARPA grants

Funding for Synchron’s technology commenced in 2012 and included grants from U.S. Defense Advanced Research Projects Agency (DARPA), United States Department of Defense (DoD) and the National Health and Medical Research Council of Australia, among other sources. Oxley’s group in Australia was the only non-US-based funded by DARPA as part of the Reliable Neural Interfaces Technology (RE-NET) program.

Barack Obama on the Stentrode™ Device (Apr 29, 2016)



All part of Obama's Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) initiative.






The First Commercial Brain Computer Interface Is Entering Human Trials

Paralyzed man with brain chip posts ‘first direct-thought’ tweet

A 62-year-old man in Australia diagnosed with amyotrophic lateral sclerosis (ALS) – a disease that causes paralysis – is now able to communicate thoughts with others with no muscle activity involved. On Thursday, he published a post on social media “using only direct thought,” the company that enabled him to do so, Synchron, announced.

Lo & behold, just imagine the possibilities!!


Synchron on wiki redirects to Beckman Coulter.
Products:
Biomek platforms, Synchron/AU analyzers, IRIS Immunochemistry system, VERIS, DxI immunoassay instruments, DxC chemistry instruments, DxH hematology instruments, Hemoccult, CEQ 2000 DNA Analysis System, Flow cytometers, Ultracentrifuge, Laboratory centrifuge.

Has an interesting acquisition history and all kinds of big pharma connections including Boehringer Ingelheim.

One of their drug products is Pradaxa-Pradaxar-Prazaxa.

Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

“With today’s approval of Pradaxa, pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.”
FDA Approval (June 21, 2021)

[Brotherman]

New arms race just dropped...




OmegaLogos link from shoutbox...

Synchron says it's the first to implant a human brain-computer interface in the US
...triggered some neurons.


FDA clears Synchron's brain-computer interface device for human trials



BusinessWire

History

Company co-founder and CEO Thomas Oxley a neurointerventionist at Mount Sinai Hospital in New York City, conceived the idea for the Stentrode in 2007. In 2010, Oxley made a cold-call pitch to Colonel Geoffrey Ling at the United States Army with a new concept for a brain-computer interface.

Oxley founded the Australian startup SmartStent in 2012, which was later renamed to Synchron in 2016. In 2016, Oxley co-published a proof-of-concept paper in Nature Biotechnology, demonstrating the potential for a neural recording device to be engineered onto a stent and chronically implanted into a blood vessel in the brain without the need for open brain surgery.

Funding - DARPA grants

Funding for Synchron’s technology commenced in 2012 and included grants from U.S. Defense Advanced Research Projects Agency (DARPA), United States Department of Defense (DoD) and the National Health and Medical Research Council of Australia, among other sources. Oxley’s group in Australia was the only non-US-based funded by DARPA as part of the Reliable Neural Interfaces Technology (RE-NET) program.

Barack Obama on the Stentrode™ Device (Apr 29, 2016)



All part of Obama's Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) initiative.






The First Commercial Brain Computer Interface Is Entering Human Trials

Paralyzed man with brain chip posts ‘first direct-thought’ tweet

A 62-year-old man in Australia diagnosed with amyotrophic lateral sclerosis (ALS) – a disease that causes paralysis – is now able to communicate thoughts with others with no muscle activity involved. On Thursday, he published a post on social media “using only direct thought,” the company that enabled him to do so, Synchron, announced.

Lo & behold, just imagine the possibilities!!


Synchron on wiki redirects to Beckman Coulter.
Products:
Biomek platforms, Synchron/AU analyzers, IRIS Immunochemistry system, VERIS, DxI immunoassay instruments, DxC chemistry instruments, DxH hematology instruments, Hemoccult, CEQ 2000 DNA Analysis System, Flow cytometers, Ultracentrifuge, Laboratory centrifuge.

Has an interesting acquisition history and all kinds of big pharma connections including Boehringer Ingelheim.

One of their drug products is Pradaxa-Pradaxar-Prazaxa.

Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

“With today’s approval of Pradaxa, pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.”
FDA Approval (June 21, 2021)

I wonder how much the monthly subscription for the ability to walks going to be? I mean they would go from disabled to able right? I bet its going to be expensive as fuck like made from the resource unobtainium unless your mad loaded.

[Michigan Swamp Buck]

Sure looks like trans-humanism at work full tilt.

Resistance is futile. You will be assimilated.

Behold the new normal. 



That's the look you will get if you try any pick up lines on the trendy trans-human babes.